Effects of Orange Juice Enriched With Vitamin D3 and Encapsulated Probiotics in High Cardiometabolic Risk Individuals
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 50
- 试验地点
- 2
- 主要终点
- Change in blood glucose concentrations
研究概览
简要总结
The effects of orange juice enriched with vitamin D3 and encapsulated probiotics (Lacticaseibacillus casei Shirota and Lacticaseibacillus rhamnosus GG) compared to conventional orange juice on several cardiometabolic and anthropometric parameters in individuals at risk of cardiovascular disease.
详细描述
This randomized, double-blind, controlled clinical trial aims to evaluate the effects of the consumption of orange juice enriched with vitamin D3 and encapsulated probiotics (Lacticaseibacillus casei Shirota and Lacticaseibacillus rhamnosus GG) compared to conventional orange juice in 50 high cardiometabolic risk volunteers. The participants must be overweight/obese with either prediabetes, and/or hypertension, and/or hyperlipidemia, and will be divided and randomly assigned into 2 groups of 25 individuals each. Participants will consume 250 ml of either orange juice enriched with vitamin D3 and encapsulated probiotics (Lacticaseibacillus casei Shirota and Lacticaseibacillus rhamnosus GG) or conventional orange juice daily for 8 weeks as an addition to their usual dietary intake. Participants will be asked to maintain their usual physical activity during the intervention period. At the beginning of the study and at 8 weeks, blood samples will be collected after 12 hours of fasting. Two-hour oral glucose tolerance test (OGTT) will be performed using a continuous glucose monitoring system at the beginning and at 8 weeks. Anthropometric measurements will be performed at the beginning and every week for 8 weeks. Basal metabolic rate (BMR) and central aortic blood pressure will be measured at the beginning, 4 weeks, and 8 weeks of intervention. Fecal samples will be collected and analyzed to study gut microbiome compositob at the intervention's beginning and at 8 weeks.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Single (Participant)
盲法说明
Double-blind
入排标准
- 年龄范围
- 18 Years 至 70 Years(Adult, Older Adult)
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Body Mass Index >= 25 kg/m2
- •Prediabetes [fasting blood glucose > 100 mg/dL], or/and
- •Hypertension [Systolic blood pressure (SBP) > 130 mmHg or Diastolic blood pressure (DBP) > 80 mmHg], or/and
- •Hyperlipidemia [total cholesterol > 200 mg/dL, and/or LDL-C > 100 mg/dL, and/or triglycerides > 150 mg/dL]
排除标准
- •Severe chronic disease (e.g. cardiovascular diseases, diabetes mellitus, kidney or liver diseases, endocrine conditions)
- •Medication that affects glycemia such as metformin, glucocorticoids, thiazide diuretics
- •Gastrointestinal disorders
- •Pregnancy
- •Lactation
- •Alcohol abuse
- •Drug dependency
- •Body weight lowering medications and/or history of bariatric surgery
- •Depression and other psychiatric diseases
- •Probiotic, prebiotic, and vitamin D supplemental intake
结局指标
主要结局
Change in blood glucose concentrations
时间窗: 8 weeks
Clinically significant change in blood glucose concentrations (mg/dL)
次要结局
- Change in blood insulin concentrations(8 weeks)
- Change in basal metabolic rate (BMR)(8 weeks)
- Change in energy intake(8 weeks)
- Change in blood lipids(8 weeks)
- Change in central aortic blood pressure(8 weeks)
- Change in body weight(8 weeks)
- Change in gut microbiome(8 weeks)
研究者
Aimilia Papakonstantinou
Assistant Professor
Agricultural University of Athens
